SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is making in its key GPS and SLS009 clinical programs.

The company is moving towards the final analysis of the Phase 3 REGAL trial of GPS in AML patients following second-line salvage therapy. Positive REGAL trial results could position it as the first and best-in-class immunotherapeutic option in this AML population.

Sellas Life Sciences is also making significant progress in developing the SLS009 clinical program for AML. Following positive Phase 2 results in high-risk molecular subtypes, the company has started dosing the first patient in the expansion cohort. Preclinical data in T-PLL demonstrated a statistically significant survival benefit for SLS009 as monotherapy and in combination with venetoclax.

In the first quarter, the company received an additional $42.6 million in proceeds from warrant exercises, further bolstering its reported $71.8 million in cash and cash equivalents as of the end of last year. Consequently, the company remains in a strong financial position to advance the clinical trials.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is a late-stage clinical biopharmaceutical company developing novel immunotherapies and targeted therapies for a broad range of cancers. Its core focus is treating hematological malignancies and solid tumors, with lead candidates targeting WT1 antigen overexpression and CDK9 inhibition to improve survival and reduce relapse.

While we acknowledge the risk and potential of SLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Penny Stocks That Aren’t Scams: Best Cheap Stocks to Buy and 8 Best Small-Cap Value Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.